# venBio Partners: portfolio, investments and team

> venBio Partners is a vc firm based in United States. 28 investments on record, latest Sept 2024. Portfolio, stages, co-investors and team.

Source: https://millionrounds.com/fund/venbio (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# venBio Partners

Filed with the SEC to raise a fund in Jul 2024, closing $505M. Last cheque observed Sep 2024.

Quiet New fund $505M, Jul 2024 VC firm

Growth Pre-IPO Seed Android Semiconductor Business Development

Cheques on record

**0%** of best year **0** **cheques in 12 months**, 28 on record

Since the last cheque **785** days **00** hrs **00** min **00** sec

Median round **$66M** Rounds led **1 of 28** Exits **2 from the portfolio** Mostly in **United States, 85%**

Pitch venBio Partners

## venBio Partners highlights

- 01 28 rounds on record
- 02 Mostly Series A and Series B: 71% of its rounds
- 03 Led 1 rounds
- 04 2 exits from the portfolio

## What they do

> Filed 4 private fund offerings with the SEC, the most recent in 2021-05 From their own website

- **Type:** VC firm (from a list, unverified)
- **Cheque size:** Not stated
- **Stages:** Growth Pre-IPO Seed Series A
- **Sectors:** Android Semiconductor Business Development
- **Based in:** San Francisco, United States
- **Cold pitches:** Not stated

## The record

Every round we can evidence, newest first **28 appearances**

- **2024** 1 round
- **Sept** **[Vicebio](https://millionrounds.com/company/vicebio)** Series B · GB · Firms' own news pages **$100M** With 7 others
- **2019** 3 rounds
- **Oct** **[Swift Health Systems](https://millionrounds.com/company/swift-health-systems)** Series C · US · FinSMEs **$45M** With 2 others
- **Sept** **[Pharvaris](https://millionrounds.com/company/pharvaris)** Series B · NL · Biospace **$66M** With 6 others
- **Apr** **[Arrakis Therapeutics](https://millionrounds.com/company/arrakis-therapeutics)** Series B · US · FinSMEs **$75M** *Led*
- **2018** 5 rounds
- **Dec** **[Akero Therapeutics](https://millionrounds.com/company/akero-therapeutics)** Series B · US · FinSMEs **$70M** With 9 others
- **Dec** **[Checkmate Pharmaceuticals](https://millionrounds.com/company/checkmate-pharmaceuticals)** US · FinSMEs **$22M** With 2 others
- **Dec** **[Impel Neuropharma](https://millionrounds.com/company/impel-neuropharma)** Series D · US · FinSMEs **$68M** With 3 others
- **Jun** **[Precision](https://millionrounds.com/company/precision)** Series B · US · FinSMEs **$110M** With 18 others
- **Jun** **[Akero Therapeutics](https://millionrounds.com/company/akero-therapeutics)** Series A · US · FinSMEs **$65M** With 3 others
- **2017** 4 rounds
- **Dec** **[Metacrine](https://millionrounds.com/company/metacrine)** Series B · US · FinSMEs **$22M** With 3 others
- **Oct** **[Harmony](https://millionrounds.com/company/harmony)** US · FinSMEs **$270M** With 6 others
- **Jun** **[Checkmate Pharmaceuticals](https://millionrounds.com/company/checkmate-pharmaceuticals)** Series B · US · FinSMEs **$27M** With 1 other
- **Jan** **[NeuroGastrx](https://millionrounds.com/company/neurogastrx)** Series A · US · FinSMEs **$45M** With 2 others
- **2016** 1 round
- **Dec** **[Impel NeuroPharma](https://millionrounds.com/company/impel-neuropharma)** Series C · US · FinSMEs **$36M** With 2 others
- **2015** 6 rounds
- **Sept** **[Oncobiologics](https://millionrounds.com/company/oncobiologics)** Venture · US **Undisclosed** With 4 others
- **Aug** **[Checkmate Pharmaceuticals](https://millionrounds.com/company/checkmate-pharmaceuticals)** Series A · US **$20M** With 1 other
- **Aug** **[Metacrine](https://millionrounds.com/company/metacrine)** Series A · US **$36M** With 3 others
- **Jul** **[Oncobiologics](https://millionrounds.com/company/oncobiologics)** Venture · US **$31M** With 3 others
- **May** **[Precision BioSciences](https://millionrounds.com/company/precision-biosciences)** Series A · US **$26M** With 5 others
- **Feb** **[Cidara Therapeutics](https://millionrounds.com/company/cidara-therapeutics)** Series B · US **$42M** With 9 others
- **2014** 4 rounds
- **Sept** **[Adaptimmune](https://millionrounds.com/company/adaptimmune)** Series A · GB **$104M** With 12 others
- **Aug** **[Bellicum Pharmaceuticals](https://millionrounds.com/company/bellicum-pharmaceuticals)** Series C · US **$94M** With 7 others
- **Apr** **[Heart Metabolics](https://millionrounds.com/company/heart-metabolics)** Series A · US **$20M** With 4 others
- **Feb** **[Aurinia Pharmaceuticals](https://millionrounds.com/company/aurinia-pharmaceuticals)** CA **$52M** With 8 others
- **2013** 2 rounds
- **Jan** **[Solstice Biologics](https://millionrounds.com/company/solstice-biologics)** Series A · US · finsmes.com **$18M** With 1 other
- **Jan** **[Labrys Biologics](https://millionrounds.com/company/labrys-biologics)** Series A · finsmes.com **$31M** With 3 others
- **2012** 2 rounds
- **Dec** **[Solstice Biologics](https://millionrounds.com/company/solstice-biologics)** Growth · US · sec.gov **$7.5M** With 1 other
- **Oct** **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Series D · US · prnewswire.com **$50M** With 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **9 named**

AR **Aaron Royston** Partner of venBio Partners LLC i Filing they signed

AD **Antoinette Delhonte** Chief Financial Officer i Form ADV

CS **Corey S. Goodman** Director of the General Partner i Filing they signed

DP **David Pezeshki** Chief Financial Officer of venBio Partners LLC i Filing they signed

KV **Kurt von Emster** Director of the General Partner i Filing they signed

PB **Paul Brooke** Director of the General Partner i Filing they signed

RS **Richard Samuel Gaster** Executive Officer i Filing they signed

RA **Robert Adelman** Director of the General Partner i Filing they signed

YY **Yvonne Yamanaka** Executive Officer i Filing they signed

We also hold **9** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$1.8B** gross assets of its funds Oct 2026

**Exempt** reporting adviser venture or small private funds

- **Legal name:** Venbio Partners LLC
- **SEC number:** CRD 290045

## Exits from the portfolio

Companies it backed that were later bought or listed **2 in all**

**[Labrys Biologics](https://millionrounds.com/company/labrys-biologics)** Bought by [Teva Pharmaceutical Industries](https://millionrounds.com/fund/teva-pharmaceutical-industries) **$825M** Jun 2014

**[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **$1.0B** Jun 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$505M**

raised in Jul 2024

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Growth Pre-IPO Seed

Median round joined **$66M** the round, not its cheque

Led 1 of 28 rounds **4%**

- **Sole investor:** Never alone
- **Last cheque:** Sept 2024
- **Exits:** 2 from the portfolio

Rounds by stage said on their site

- Series A said *9*
- Series B *8*
- Series C *3*
- Series D *2*
- Venture *2*
- Growth said *-*
- Pre-IPO said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [5AM Ventures](https://millionrounds.com/fund/5am-ventures) 4
- [F-Prime Capital](https://millionrounds.com/fund/f-prime) 4
- [Perceptive Advisors](https://millionrounds.com/fund/perceptive-advisors) 4
- [Alexandria Real Estate Equities](https://millionrounds.com/fund/alexandria) 3
- [Apple Tree Partners](https://millionrounds.com/fund/apple-tree-partners) 3
- [OrbiMed](https://millionrounds.com/fund/orbimed) 3

**Pitching venBio Partners?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as venBio Partners. A count of rooms they were both in, not a relationship either has claimed.

[**5AM Ventures** VC firm **4** rounds together](https://millionrounds.com/fund/5am-ventures)[**F-Prime Capital** VC firm **4** rounds together](https://millionrounds.com/fund/f-prime)[**Perceptive Advisors** Asset manager **4** rounds together](https://millionrounds.com/fund/perceptive-advisors)[**Alexandria Real Estate Equities** VC firm **3** rounds together](https://millionrounds.com/fund/alexandria)[**Apple Tree Partners** VC firm **3** rounds together](https://millionrounds.com/fund/apple-tree-partners)[**OrbiMed** Private equity **3** rounds together](https://millionrounds.com/fund/orbimed)[**Osage University Partners** VC firm **3** rounds together](https://millionrounds.com/fund/osage-university-partners)[**RA Capital Management** Private equity **3** rounds together](https://millionrounds.com/fund/ra-capital-management)[**Sabby Capital** Private equity **3** rounds together](https://millionrounds.com/fund/sabby-capital)[**Aeris Capital** Growth equity **2** rounds together](https://millionrounds.com/fund/aeris-capital)[**Aisling Capital** Private equity **2** rounds together](https://millionrounds.com/fund/aisling-capital)[**Atlas** Private equity **2** rounds together](https://millionrounds.com/fund/atlas-2)

## Recently backed

The latest companies venBio Partners put money into.

[**Vicebio** $100M · Sept 2024](https://millionrounds.com/company/vicebio)[**Pharvaris** $66M · Sept 2019](https://millionrounds.com/company/pharvaris)[**Arrakis Therapeutics** $75M · Apr 2019](https://millionrounds.com/company/arrakis-therapeutics)[**Akero Therapeutics** $70M · Dec 2018](https://millionrounds.com/company/akero-therapeutics)[**Checkmate Pharmaceuticals** $22M · Dec 2018](https://millionrounds.com/company/checkmate-pharmaceuticals)[**Metacrine** $22M · Dec 2017](https://millionrounds.com/company/metacrine)

## Quick answers about venBio Partners

### What does venBio Partners invest in?

venBio Partners invests most often at Series A and Series B (71% of the rounds on record), in sectors such as Android, Semiconductor and Business Development.

### How active is venBio Partners?

28 investments on record, 0 of them in the last 12 months, and it led 1. The most recent was in Sept 2024.

### What has venBio Partners invested in recently?

Its most recent investments on record: Vicebio (Series B, Sept 2024), Swift Health Systems (Series C, Oct 2019) and Pharvaris (Series B, Sept 2019).

### How big are venBio Partners's cheques?

The median round it joins is $66M.

### Does venBio Partners lead rounds?

Sometimes: it led 1 of its 28 investments on record (4%).

### Where does venBio Partners invest?

Most of the companies it backs are in the United States (85%) and the United Kingdom (7%).

### Is venBio Partners investing now?

No investments in the last 12 months; the latest was in Sept 2024.

### Who does venBio Partners invest alongside?

Most often 5AM Ventures (4 rounds together), F-Prime Capital (4 rounds together) and Perceptive Advisors (4 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=venbio) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=venbio)